Hear from Sarah Cannon experts on OncLive News Filter
News Articles List
More than 135 abstracts accepted for presentation across all phases of drug development
Dr. Ishwaria Subbiah to lead new programs focused on patient and clinical workplace experiences
Dr. Vivek Subbiah to serve as chief, early-phase drug development across SCRI's Research Network
Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today...
Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations...
President Biden’s renewed focus on the Cancer Moonshot is welcome news.
Early-phase research expert, Cesar Perez, MD, leads the newest Sarah Cannon Research Institute at FCS drug development unit conveniently located...
Dr. Majhail will focus on the continued expansion of the Sarah Cannon Transplant and Cellular Therapy Network Centers of Excellence providing...
119 Abstracts and Presentations Featuring Sarah Cannon’s Clinical Research and Care Insights
Daiichi Sankyo and Sarah Cannon Research Institute announced that the first patient has been dosed in the first-in-human phase 1 study evaluating...
The consortium of prominent public and private research institutions will use HCA Healthcare’s vast data on COVID-19 hospital care to improve...
In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.
Sarah Cannon announced that 53 abstracts and presentations authored by Sarah Cannon experts have been selected for presentation at the upcoming...
The trusted cancer experts at Mission Health join HCA Healthcare’s Cancer Institute to enhance cancer services for patients across western North...
Advocacy Champions are ASCO volunteers who have made meaningful contributions to ASCO’s advocacy activities throughout the year to ensure that...
This partnership brings together Lyell’s research and development of cell-based immunotherapies and Sarah Cannon’s expertise in designing and...
Through the partnership, AON and Sarah Cannon will offer clinical trial options to patients across several locations within AON’s network of ...
More Than 110 Abstracts and Presentations will be Presented by Sarah Cannon Researchers; Dr. Howard A. “Skip” Burris III Serves as ASCO® President...
The first patient has been dosed in a first-in-human phase 1 study evaluating DS-6157, an investigational GPR20 directed antibody drug conjugate...